Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

21. Effects of exercise interventions on respiratory drive (Emgdi%max) in patients with chronic obstructive pulmonary disease: a Systematic Review and Meta-Analysis Full Text available with Trip Pro

Effects of exercise interventions on respiratory drive (Emgdi%max) in patients with chronic obstructive pulmonary disease: a Systematic Review and Meta-Analysis Inplasy Protocol 485 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

22. Addressing therapeutic questions to help Canadian physicians optimize COPD management for their patients during the Covid-19 pandemic

. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. 8. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105941 9. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223 (...) distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chronic lung disease we have placed a high value on limiting exposure based on prior experience with influenza. COPD Management – General Statement In the absence of direct or indirect data that use of current inhaled COPD therapies impacts the severity of SARS-CoV-2 infection, we recommend that maintenance and exacerbation management for COPD

2020 Canadian Thoracic Society

23. Inhaled Salbutamol Shortage – Mitigation Strategy for COPD

Inhaled Salbutamol Shortage – Mitigation Strategy for COPD CTS Guidance on Salbutamol Shortage - April 13, 2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for COPD April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) to meet demand for the drug. A tier 3 shortage is a shortage with the greatest potential impact on the Canadian drug supply and healthcare systems by virtue of availability of alternate supplies, ingredients, or therapies.” 3) Restrictions have been put in place by wholesalers and distributors to limit the supply of salbutamol which means that most patients will receive only one salbutamol inhaler or a one month supply at a time . 4) It is possible that the surge in demand relates to individuals

2020 Canadian Thoracic Society

24. Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis

: Item in Clipboard Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis Ailing Cao et al. Clin Rehabil . 2020 Aug . Show details Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Authors , , , Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI: Item (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis , , , Affiliations Expand Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI

2020 EvidenceUpdates

25. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. Full Text available with Trip Pro

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two dose levels (...) of inhaled glucocorticoid in patients with moderate-to-very-severe COPD and at least one exacerbation in the past year, we assigned patients in a 1:1:1:1 ratio to receive twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 μg or 160 μg of budesonide], a LAMA [18 μg of glycopyrrolate], and a LABA [9.6 μg of formoterol]) or one of two dual therapies (18 μg of glycopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol). The primary end point

2020 NEJM

26. Physiotherapetic Approach in Elderly With COPD: A Systematic Review Full Text available with Trip Pro

BY 4.0 License. Abstract Background: The number of elderly individuals with chronic obstructive pulmonary disease (COPD) is increasing, resulting in high costs, especially in the Brazilian public health system. Scientific studies show that the physical therapy approach has benefits and assists in pulmonary rehabilitation, however, it is necessary to know the interventions that optimize the clinical and functional improvement of the individual. Objective: To analyze physical therapy interventions (...) individuals with chronic obstructive pulmonary disease (COPD) is increasing, resulting in high costs, especially in the Brazilian public health system. Scientific studies show that the physical therapy approach has benefits and assists in pulmonary rehabilitation, however, it is necessary to know the interventions that optimize the clinical and functional improvement of the individual. Objective: To analyze physical therapy interventions and their main outcomes in elderly with COPD. Methods: Five

2020 Research Square

27. Home noninvasive positive-pressure ventilation reduces mortality and intubations in COPD with hypercapnia. (Abstract)

Home noninvasive positive-pressure ventilation reduces mortality and intubations in COPD with hypercapnia. Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2020;323:455-65. 32016309.

2020 Annals of Internal Medicine

28. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. Full Text available with Trip Pro

Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD), yet much of COPD risk remains unexplained.To determine whether dysanapsis, a mismatch of airway tree caliber to lung size, assessed by computed tomography (CT), is associated with incident COPD among older adults and lung function decline in COPD.A retrospective cohort study of 2 community-based samples: the Multi-Ethnic Study (...) of Atherosclerosis (MESA) Lung Study, which involved 2531 participants (6 US sites, 2010-2018) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD), which involved 1272 participants (9 Canadian sites, 2010-2018), and a case-control study of COPD: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), which involved 2726 participants (12 US sites, 2011-2016).Dysanapsis was quantified on CT as the geometric mean of airway lumen diameters measured at 19 standard anatomic locations

2020 JAMA

29. Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Approximately 12 million adults in the United States receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it is the fourth leading cause of death. Chronic obstructive pulmonary disease refers to a group of diseases that cause airflow obstruction and a constellation of symptoms, including cough (...) , sputum production, and shortness of breath. The main risk factor for COPD is tobacco smoke, but other environmental exposures also may contribute. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2020 Report aims to provide a nonbiased review of the current evidence for the assessment, diagnosis, and treatment of patients with COPD. To date, no conclusive evidence exists that any existing medications for COPD modify mortality. The mainstay of treatment for COPD is inhaled

2020 Annals of Internal Medicine

30. Pharmacologic Management of COPD: An Official ATS Clinical Practice Guideline

No Additional Therapy? Conclusions Summary of Recommendations In patients with chronic obstructive pulmonary disease (COPD) who complain of dyspnea or exercise intolerance, we recommend long-acting b 2 -agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence). In patients with COPD who complain of dyspnea or exercise intolerance despite dual therapy with LABA/LAMA, we suggest the use of triple therapy (...) advise against the use of maintenance oral corticosteroid therapy (conditional recommendation, low certainty evidence). In individuals with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy, we suggest that opioid-based therapy be considered for dyspnea management, within a personalized shared decision- making approach (conditional recommendation, very low certainty evidence). Introduction The Global Initiative for Chronic Obstructive Lung Disease 2019 report de?nes

2020 American Thoracic Society

31. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis Full Text available with Trip Pro

, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22. 8. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Suppl 41):46s–53s. 9. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for diagnosis, management and prevention of chronic obstructive lung disease: the GOLD science committee (...) , Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791. 16. McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:CD003900. 17. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations

2020 BMC complementary medicine and therapies

32. Kinesiotherapeutic interventions in diaphragmatic mobility of patients with chronic obstructive lung disease: systematic review Full Text available with Trip Pro

interventions in diaphragmatic mobility of patients with chronic obstructive lung disease: systematic review Gilson Rosa de Jesus, Milena Santos Peixoto, Sidney de Souza Oliveira Resumo This study analyzed the pathophysiological impacts of Chronic Obstructive Pulmonary Disease (COPD) on the respiratory system and the benefits of kinesiotherapeutic interventions on diaphragmatic mobility in patients affected by COPD. Systematic literature review carried out in the Scielo, Medline, VHL, Lilacs and PEDro (...) the beneficial effects of different Kinesiotherapy Intervention programs on physical health and quality of life, reduction of respiratory symptoms and risk of mortality, increased mobility of the rib cage, diaphragmatic functionality, functional capacity and respiratory muscle strength of patients affected by COPD. Keywords : chronic obstructive pulmonary disease, respiratory rehabilitation, kinesiotherapeutic interventions, diaphragmatic dysfunction. Texto completo: Referências Datasus. Sistema de

2020 Revista Brasileira de Fisiologia do Exercício

33. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. Full Text available with Trip Pro

Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. Meta-analyses have suggested that initiating pulmonary rehabilitation after an exacerbation of chronic obstructive pulmonary disease (COPD) was associated with improved survival, although the number of patients studied was small and heterogeneity was high. Current guidelines recommend that patients enroll in pulmonary rehabilitation after hospital (...) discharge.To determine the association between the initiation of pulmonary rehabilitation within 90 days of hospital discharge and 1-year survival.This retrospective, inception cohort study used claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, at 4446 acute care hospitals in the US. The final date of follow-up was December 31, 2015.Initiation of pulmonary rehabilitation within 90 days of hospital discharge.The primary outcome was all-cause mortality at 1 year. Time

2020 JAMA

34. The effectiveness of supplemental oxygen during exercise training in patients with chronic obstructive pulmonary disease who show sever exercise-induced desaturation: a protocol for a meta-regression analysis and systematic review Full Text available with Trip Pro

in patients with chronic obstructive pulmonary disease (COPD) who show exercise-induced desaturation. Although some meta-analyses examined the efficacy of supplemental oxygen during exercise training, these studies concluded that it does not further improve exercise tolerance compared to exercise training alone. However, supplemental oxygen during exercise training may be effective to improve exercise tolerance in COPD patients with severe desaturation during exercise under breathing room air (...) of this study is that it is a systematic review with meta-regression analysis to elucidate the effectiveness of supplemental oxygen during exercise training in patients with COPD who show sever exercise-induced desaturation. However, the quality and number of studies included meta-analysis may be low. Systematic review registration: Registration number, UMIN000039960. Keywords supplemental oxygen, desaturation, hypoxemia, chronic obstructive pulmonary disease, exercise training Description Of The Condition

2020 Research Square

35. Acupuncture techniques for COPD: a systematic review Full Text available with Trip Pro

(identifier: ). Introduction Chronic obstructive pulmonary disease (COPD) is one of the most prevalent lung diseases, with 251 million cases globally in 2016, and is the 4th cause of death worldwide, with more than 3.2 million instances in 2015 [ ]. These numbers are expected to increase [ ]. COPD is characterised by a chronic and irreversible airflow obstruction caused by an inflammation in the airways and lung parenchyma which leads to structural abnormalities in the airways. These alterations specially (...) at Dingchuan (EX-B1) on the pulmonary function of patients with COPD at acute stage. Zhongguo Zhen Jiu Chin Acupunct Moxibustion. 2011;31(2):97–100. 16. Zhang QY, Lv XD, Feng Y. Long-term effect of Chinese medicine moxibustion on COPD combined with type 2 respiratory failure. Chinese J Tradit Med Sci Technol. 2016;23(02):193–5. 17. Yang XQ, Fu DY. Effects of moxibustion on chronic obstructive pulmonary disease with pulmonary qi deficiency. People’s Military Med Officer. 2016;59(10):1036–7. 18. Wang WH, Qiu

2020 BMC complementary medicine and therapies

36. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT Full Text available with Trip Pro

C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Point-of-care testing resulted in a 20% absolute reduction in patient-reported antibiotic consumption over 4 weeks, without impairing chronic obstructive pulmonary disease health status. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Nick A Francis 1, * , David Gillespie 2 , Patrick White 3

2020 NIHR HTA programme

37. Do Antibiotics Improve Patient Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Full Text available with Trip Pro

, and severity of COPD exacerbations. Thorax . 2002 ; 57 : 759–764 | | | , x 7 Seemungal, T., Harper-Owen, R., Bhowmik, A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2001 ; 164 : 1618–1623 | | | , x 8 Sethi, S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?. Proc Am Thorac Soc . 2004 ; 1 : 109–114 | | | , x 9 Bafadhel, M., McKenna, S (...) ., Frei, A., Steurer-Stey, C.A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2018 ; 10 : CD010257 Limitations of this meta-analysis include no consideration of underlying chronic obstructive pulmonary disease severity across trials because of poor reporting of lung function and other parameters. Studies were not limited to patients with suspected bacterial infection, who demonstrate the greatest benefit from antibiotics. Thus, the lack

2020 Annals of Emergency Medicine Systematic Review Snapshots

38. COPD and COVID-19 for Healthcare Professionals

. There is no evidence to use or not to use oral or inhaled corticosteroids outside usual guidelines in COPD patients with COVID19. Antibiotics should be issued only if suspicion of secondary bacterial infection.” Please refer to that document. Please also refer to the NICE Rapid Guideline for the community-based care of patients with chronic obstructive pulmonary disease (COPD): https://www.nice.org.uk/guidance/ng168 This reiterates the importance of smoking cessation. Strongly encourage patients with COPD who (...) ), there is no routine indication to take rescue antibiotics or additional oral steroids. Do not offer patients with COPD a short course of oral corticosteroids and/or antibiotics to keep at home unless clinically indicated, as set out in the NICE guideline on chronic obstructive pulmonary disease in over 16s. There should be NO alteration to advanced rescue-pack prescribing or stockpiling inhalers. These seriously compromise the medicines supply chain and equitable access. Best practice at all times

2020 British Thoracic Society

39. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial Full Text available with Trip Pro

Permalink Copy Page navigation Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Respiratory Research Unit, Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark henrik.hansen.09@regionh.dk. 2 Department of Physical and Occupational Therapy, Bispebjerg Hospital (...) and Infectious Diseases, Hillerød Hospital, Hillerød, Denmark. 9 Department of Public Health, University of Copenhagen Faculty of Health Sciences, Copenhagen, Denmark. PMID: 32229541 DOI: Item in Clipboard Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial Henrik Hansen et al. Thorax . 2020 May . Show details Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Authors

2020 EvidenceUpdates

40. Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review Full Text available with Trip Pro

Obstructive Pulmonary Disease: A Systematic Review Abstract American Journal of Respiratory and Critical Care Medicine 2020;201:A2328 Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review x B. Rangelov , x A.L. Young , x J. Jacob , x A.P. Cahn , x S. Lee , x F.J. Wilson , x D.J. Hawkes , x J.R. Hurst , 25 Broadway New York, NY 10004 (212) 315-8600 ATS Journals Services General Information Copyright © 1987-2020 American Thoracic Society, All Rights Reserved. (...) Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review | A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES Cookies Notification This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Search Menu Connect With Us Search in: A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES > > > Thoracic Imaging at Exacerbation of Chronic

2020 A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES